{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:27:15Z","timestamp":1790803635647,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Recordati Rare Diseases","award":["KDP-12-3\/PALY-2022"],"award-info":[{"award-number":["KDP-12-3\/PALY-2022"]}]},{"DOI":"10.13039\/501100012550","name":"National Research, Development and Innovation Fund","doi-asserted-by":"publisher","award":["KDP-12-3\/PALY-2022"],"award-info":[{"award-number":["KDP-12-3\/PALY-2022"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The anti-GD2 monoclonal antibody dinutuximab beta has become standard of care maintenance therapy for high-risk neuroblastoma (HR-NB) in the first-line setting and is also approved in the relapsed\/refractory setting. We present a retrospective review of 37 children with HR-NB included in the Hungarian Childhood Cancer Registry who received dinutuximab beta (first-line maintenance therapy, n = 31; relapsed\/refractory, n = 6). Methods: All patients received dinutuximab beta continuously over the first 10 days of each 35-day cycle, with dosing based on body surface area\/weight. Five cycles were planned, with further cycles administered at the treating physician\u2019s discretion. Results: At data cutoff, the overall disease control rate was 54.1% (20\/37) (complete response, 51.4% (19\/37); partial response, 0.0% (0\/37), stable disease, 2.7% [1\/37]); two patients (5.4%) had progressive disease, and 15 patients (40.5%) had died. The 5-year overall survival (OS) and event-free survival (EFS) rates in the overall population were 63.3% (95% confidence interval, 49.1\u221281.7) and 56.2% (95% confidence interval, 42.1\u221275.0), respectively. Grade 3 or 4 adverse events (including blood and lymphatic system disorders, hypoxia, hypotension, and capillary leak syndrome) were generally consistent with dinutuximab beta\u2019s known safety profile. Conclusions: Dinutuximab beta was an effective immunotherapy for patients with HR-NB in routine clinical practice, with a generally manageable side effect profile.<\/jats:p>","DOI":"10.3390\/jcm14186641","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:08:03Z","timestamp":1758542883000},"page":"6641","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network"],"prefix":"10.3390","volume":"14","author":[{"given":"M\u00e1rk","family":"Hern\u00e1df\u0151i","sequence":"first","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary"},{"name":"Bethesda Children\u2019s Hospital, 1146 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rton","family":"Szabados","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary"},{"name":"Pediatric Center, Semmelweis University, 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edit","family":"Br\u00fcckner","sequence":"additional","affiliation":[{"name":"Pediatric Center, Semmelweis University, 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Varga","sequence":"additional","affiliation":[{"name":"Velkey L\u00e1szl\u00f3 Children\u2019s Health Center, B.A.Z. County Central Hospital and University Teaching Hospital, 3529 Miskolc, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-8975","authenticated-orcid":false,"given":"P\u00e9ter","family":"Hauser","sequence":"additional","affiliation":[{"name":"Pediatric Center, Semmelweis University, 1094 Budapest, Hungary"},{"name":"Velkey L\u00e1szl\u00f3 Children\u2019s Health Center, B.A.Z. County Central Hospital and University Teaching Hospital, 3529 Miskolc, Hungary"},{"name":"Department of Pediatric Bone Marrow & Stem Cell Transplant, South-Pest Hospital Centre\u2013National Institute for Infectology and Hematology, 1097 Budapest, Hungary"},{"name":"Faculty of Health Sciences, University of Miskolc, Miskolc-Egyetemv\u00e1ros, 3515 Miskolc, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-6620","authenticated-orcid":false,"given":"G\u00e1bor","family":"Ott\u00f3ffy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of P\u00e9cs Medical School, 7623 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Vojcek","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of P\u00e9cs Medical School, 7623 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Csan\u00e1di","sequence":"additional","affiliation":[{"name":"Heim P\u00e1l National Pediatric Institute, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8290","authenticated-orcid":false,"given":"Gabriella","family":"Kert\u00e9sz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Bone Marrow & Stem Cell Transplant, South-Pest Hospital Centre\u2013National Institute for Infectology and Hematology, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5410-1187","authenticated-orcid":false,"given":"Zsuzsanna","family":"Jakab","sequence":"additional","affiliation":[{"name":"Pediatric Center, Semmelweis University, 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-3790","authenticated-orcid":false,"given":"Gergely","family":"Ag\u00f3cs","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary"},{"name":"Department of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4298-2746","authenticated-orcid":false,"given":"Mikl\u00f3s","family":"Garami","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary"},{"name":"Pediatric Center, Semmelweis University, 1094 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13046-022-02281-w","article-title":"Recent advances in the developmental origin of neuroblastoma: An overview","volume":"41","author":"Ponzoni","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/ijc.31222","article-title":"Neuroblastoma among children in Southern and Eastern European cancer registries: Variations in incidence and temporal trends compared to US","volume":"142","author":"Georgakis","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1148\/rg.2018170132","article-title":"Updates in Diagnosis, Management, and Treatment of Neuroblastoma","volume":"38","author":"Swift","year":"2018","journal-title":"Radiographics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1200\/JCO.2005.05.571","article-title":"Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group","volume":"23","author":"London","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.22.01946","article-title":"Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification","volume":"41","author":"Bender","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1158\/1078-0432.CCR-11-1409","article-title":"New strategies in refractory and recurrent neuroblastoma: Translational opportunities to impact patient outcome","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/1060028016632013","article-title":"Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma","volume":"50","author":"Ploessl","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ladenstein, R., P\u00f6tschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Ash, S., Laureys, G., Brock, P., Michon, J.M., and Owens, C. (2020). Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, 12.","DOI":"10.3390\/cancers12020309"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e28473","DOI":"10.1002\/pbc.28473","article-title":"Neuroblastoma","volume":"68","author":"Chung","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): A multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"10013","DOI":"10.1200\/JCO.2019.37.15_suppl.10013","article-title":"Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front\u2013line high-risk neuroblastoma patients: Early results from the HR-NBL1\/SIOPEN trial","volume":"37","author":"Ladenstein","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_13","unstructured":"European Medicines Agency (2025, September 05). Qarziba (Dinutuximab Beta) Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/qarziba-epar-product-information_en.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1200\/JCO.2019.37.15_suppl.10014","article-title":"Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial","volume":"37","author":"Lode","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_15","unstructured":"SIOPEN Research Network (2025, September 03). High Risk Neuroblastoma Study 1 (HR-NBL1). Available online: https:\/\/www.siopen.org\/siopen-clinical-trials-1\/hr1."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.ejca.2005.12.029","article-title":"Neuroblastoma in hungary","volume":"42","author":"Parker","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/CCI.20.00074","article-title":"Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future","volume":"4","author":"Liang","year":"2020","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2009.27.3524","article-title":"Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1\/SIOPEN study","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4143\/crt.2016.511","article-title":"Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study","volume":"50","author":"Amoroso","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): An international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40272-021-00469-9","article-title":"Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance","volume":"23","author":"Barone","year":"2021","journal-title":"Paediatr. Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting","volume":"35","author":"Park","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_24","unstructured":"R Core Team (2024, December 16). R: A Language and Environment for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Therneau, T.M., and Grambsch, P.M. (2000). Modeling Survival Data: Extending the Cox Model, Springer.","DOI":"10.1007\/978-1-4757-3294-8"},{"key":"ref_26","unstructured":"Therneau, T.M., Lumley, T., Atkinson, E., and Crowson, C. (2024, December 16). A Package for Survival Analysis in R. Available online: https:\/\/CRAN.R-project.org\/package=survival."},{"key":"ref_27","unstructured":"Kassambara, A., Kosinski, M., Biecek, P., and Fabian, S. (2024, December 16). Survminer: Drawing Survival Curves Using \u2018ggplot2\u2019. Available online: https:\/\/CRAN.R-project.org\/package=survminer."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1470-2045(24)00202-X","article-title":"Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"25","author":"Corbacioglu","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S2352-4642(18)30023-3","article-title":"Assessing the feasibility and validity of the Toronto Childhood Cancer Stage Guidelines: A population-based registry study","volume":"2","author":"Aitken","year":"2018","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7150\/ijms.48393","article-title":"Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells","volume":"18","author":"Waetzig","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1002\/ijc.29138","article-title":"RIST: A potent new combination therapy for glioblastoma","volume":"136","author":"Nonnenmacher","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.mph.0000183863.10792.d4","article-title":"A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer","volume":"27","author":"Kieran","year":"2005","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.24794","article-title":"A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer","volume":"61","author":"Robison","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wieczorek, A., \u017bebrowska, U., Ussowicz, M., Sok\u00f3\u0142, A., Stypi\u0144ska, M., Dembowska-Bagi\u0144ska, B., Pawi\u0144ska-W\u0105sikowska, K., and Balwierz, W. (2023). Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory\/Relapsed Settings-Real-World Data. J. Clin. Med., 12.","DOI":"10.3390\/jcm12165252"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Giljevi\u0107, J.S., Raja\u010di\u0107, N., Mikuli\u0107, D., and Bato\u0161, A.T. (2022). Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia. Children, 9.","DOI":"10.3390\/children9070943"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e28716","DOI":"10.1097\/MD.0000000000028716","article-title":"Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava","volume":"101","year":"2022","journal-title":"Medicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e024957","DOI":"10.1136\/bmjopen-2018-024957","article-title":"Workforce crisis in primary healthcare worldwide: Hungarian example in a longitudinal follow-up study","volume":"9","author":"Papp","year":"2019","journal-title":"BMJ Open"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs, N., P\u00e1link\u00e1s, A., Sipos, V., Nagy, A., Harsha, N., K\u0151r\u00f6si, L., Papp, M., \u00c1d\u00e1ny, R., Varga, O., and S\u00e1ndor, J. (2019). Factors Associated with Practice-Level Performance Indicators in Primary Health Care in Hungary: A Nationwide Cross-Sectional Study. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16173153"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"N\u00e9meth, K., Ny\u00e1ri, T.A., and Lantos, T. (2024). Patterns of Childhood Cancer Mortality in Hungary Since the Turn of the Millennium, Including the Two Years of the COVID-19 Pandemic. Cancers, 16.","DOI":"10.3390\/cancers16233961"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6641\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:27Z","timestamp":1760035587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":39,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14186641"],"URL":"https:\/\/doi.org\/10.3390\/jcm14186641","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]}}}